Correlation between PD-L1 Expression, Clinicopathological Factors, and Metastasis Risk in Colorectal Cancer Patients
Table 1
Patients’ clinicopathological and demographic characteristics.
Parameters
PD-L1 positive (n = 20)
PD-L1 negative (n = 60)
value
Gender
0.245
Male
8 (40%)
33 (55%)
Female
12 (60%)
27 (45%)
Age at disease onset, years
56.9 ± 13
58.5 ± 14.4
0.671
Survival period, days
543.5
532.5
0.885
Disease-free survival
447
435
Cases outcome
0.573
Mortality
7 (35%)
17 (28.3%)
Survival
13 (65%)
43 (71.7%)
Causes of death
0.350
Cancer
6 (30%)
8 (13.3%)
Intracerebral hemorrhage
0 (0%)
2 (3.3%)
Surgery
1 (5%)
7 (11.7%)
Stage
0.077
1
0 (0%)
3 (5%)
2
9 (45%)
13 (21.7%)
3
9 (45%)
30 (50%)
4
2 (10%)
8 (13.3%)
TNM
T
1
0 (0%)
3 (5%)
2
9 (45%)
19 (31.7%)
3
9 (45%)
30 (50%)
4
2 (10%)
8 (13.3%)
N
0
3 (15%)
23 (38.3%)
1
12 (60%)
28 (47.7%)
2
5 (25%)
9 (15%)
M
10 (50%)
14 (23.3%)
0.024
Tumor differentiation
Poor
2 (10%)
3 (5%)
Moderate
17 (85%)
41 (68.3%)
Well
1 (5%)
16 (27.7%)
CEA
7 (35%)
18 (30%)
0.676
Metastasis site
0.074
Bladder
1 (5%)
1 (1.7%)
Bone
0 (0%)
1 (1.7%)
Liver
4 (20%)
7 (11.7%)
Lung
3 (15%)
4 (6.7%)
Ovary
1 (5%)
0 (0%)
Vertebrae
1 (5%)
0 (0%)
Spleen
0 (0)
1 (1.7)
CEA: carcinoembryonic antigen. Bold and ∗ indicate a significance level of p value less than 0.05. Qualitative data are presented as frequencies (%), quantitative variables with non-normal distribution are presented as median and quantitative variables with normal distribution are presented as mean ± SD.
